{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:17:51Z","timestamp":1758050271325,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bulcan.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:11:38Z","timestamp":1698322298000},"page":"1234-1243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligroprogression sous nivolumab du cancer bronchique non \u00e0 petites cellules m\u00e9tastatiques trait\u00e9es par radioth\u00e9rapie"],"prefix":"10.1016","volume":"110","author":[{"given":"Ana\u00efs","family":"Gag\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-7161","authenticated-orcid":false,"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Belliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Janicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Bourrachot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Rolland-Debord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.bulcan.2023.09.006_bib0095","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.09.006_bib0100","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.09.006_bib0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.bulcan.2023.09.006_bib0110","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)","volume":"387","author":"Herbst","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bulcan.2023.09.006_bib0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bulcan.2018.04.012","article-title":"Definitions of oligometastatic disease and new treatment concepts","volume":"105","author":"Kissel","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2023.09.006_bib0120","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer","volume":"32","author":"Iyengar","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.09.006_bib0125","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2023.09.006_bib0130","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1\u00a0blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.bulcan.2023.09.006_bib0135","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.21037\/jtd.2019.12.23","article-title":"Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1\u00a0\u2265\u00a050\u00a0% who progress on first-line immunotherapy: real-world data from a European cohort","volume":"11","author":"Metro","year":"2019","journal-title":"J Thor Dis"},{"issue":"6","key":"10.1016\/j.bulcan.2023.09.006_bib0140","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","article-title":"Clinical features and management of acquired resistance to PD-1\u00a0axis inhibitors in 26\u00a0patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2023.09.006_bib0145","first-page":"4368","article-title":"Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer Transl Lung","volume":"10","author":"Zhen","year":"2021","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.bulcan.2023.09.006_bib0150","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.09.006_bib0155","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.09.006_bib0160","first-page":"115","article-title":"Stereotactic ablative radiotherapy for oligo-progressive disease refractory to systemic therapy in non-small cell lung cancer: a registry-based phase II randomized trial (SUPPRESS-NSCLC)","volume":"33","author":"Bahig","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.09.006_bib0165","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non\u2013small cell lung cancer","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.09.006_bib0170","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2023.09.006_bib0175","first-page":"895","article-title":"pembrolizumab with or without radiotherapy for metastatic non small cell lung cancer: a pooled analysis of two randomized trials","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"issue":"305","key":"10.1016\/j.bulcan.2023.09.006_bib0090","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation\u00a0\u2013\u00a0radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123003855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123003855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:02Z","timestamp":1757792282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0007455123003855"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.09.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oligroprogression sous nivolumab du cancer bronchique non \u00e0 petites cellules m\u00e9tastatiques trait\u00e9es par radioth\u00e9rapie","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}